With Oxford Nanopore's oversubscribed offering pulling in $59 million (£35 million), the British startup has the money to scale up production of its sequencer while developing new uses for the underlying technology.
While early adopters of Illumina's $1,000 genome machine the HiSeq X Ten have been testing the system for months, researchers from less wealthy organizations have had no access to the technology. In a limited way that changed this week, when the Garvan Institute of Medical Research, DNAnexus and AllSeq teamed up to share data from a HiSeq X Ten.
Venter has gone to Mountain View to make his latest hire, nabbing Franz Och to build a Google Translate for genomics.
While Google-backed personal genetics startup 23andMe is still working through its disagreements with the FDA, the company has impressed another part of the federal machine enough to win funding.
The British government has unveiled a major funding boost for its 100,000 Genomes Project, with a further $506 million (£300 million) set to be spent over the next four years. Illumina is responsible for more than half of the cash, with the U.S. sequencing giant due to invest $273 million in England.
Scientists from the Broad Institute are unveiling new genomic findings from thousands of schizophrenia patients that could lead to new molecular targets. And, thanks to the philanthropist Ted Stanley, they'll have $650 million to help find out.
When Illumina unveiled its HiSeq X Ten in January, the alignment between its capabilities and the needs of England's 100K Genome Project were clear. The project aims to sequence 100,000 genomes by 2017 for around $160 million, figures that only look achievable using the massive output and relatively low costs of the HiSeq X Ten. This week the tie-up became official.
While Apple, Google and Samsung are all trying to persuade people to use their mobile technology to create personal health hubs, Illumina plans to take the concept further still. The genomic giant is working to turn smartphones into "molecular stethoscopes" that could change how patients interact with the healthcare and research ecosystems.
In the months since Google unveiled its cloud-based genomics platform, the only public sign of the project's evolution has been the frequent updates to its underlying code on GitHub. That changed this week when Google Genomics signed up a customer: Autism Speaks.
Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.